The Latin America, Middle East and Africa Multiple Myeloma Market would witness market growth of 16.5% CAGR during the forecast period (2023-2029).
The growth of nanomedicine platforms, the increasing usage of microRNA therapies, and the ongoing development of efficient and secure medications all contribute to developing the multiple myeloma market. The medication sector is projected to grow when histone deacetylase (HDAC) inhibitors and monoclonal antibodies are added to the current treatment options. Clinicians choose biological therapy using monoclonal antibodies like darzalex and empliciti because of the documented clinical profile.
As the disease's symptoms start manifesting as active myeloma, doctors determine whether to use the second and third lines of therapy. Stem cell transplant operations are typically included in the first line. The method entails storing bone marrow and stem cells outside the patient's body, followed by a strong dosage of chemotherapy or radiation and bone marrow replenishment and stem cells. There is a high demand for allogeneic stem cell transplants rather than autologous ones, the two main forms of stem cell transplants.
In Latin America, many treatment methods of MM have been tested. The disease had little effect from chemotherapy combined with dexamethasone, but developing new medications like protease inhibitors or IMiDs significantly improved the prospects for MM patients. Thalidomide was the first medication to demonstrate success, and it was already available in numerous Latin American nations, including Brazil, as it is inexpensive and thus accessible in this region. MM therapy combines this medication with dexamethasone or dexamethasone and alkylating drugs. The rising prevalence of multiple myeloma and the availability of treatment drugs are propelling the advancement of the regional market.
The Brazil market dominated the LAMEA Multiple Myeloma Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $772.4 Million by 2029. The Argentina market is exhibiting a CAGR of 17.1% during (2023 - 2029). Additionally, The UAE market would showcase a CAGR of 16.2% during (2023 - 2029).
Based on End User, the market is segmented into Hospitals, Clinics, and Others. Based on Disease Type, the market is segmented into Active Multiple Myeloma and Smoldering Multiple Myeloma. Based on Drug Type, the market is segmented into Protease Inhibitors, Monoclonal Antibody, Chemotherapy and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Multiple Myeloma Market is Projected to reach USD 37.5 Billion by 2029, at a CAGR of 9.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Bristol Myers Squibb Company, Amgen, Inc., AbbVie, Inc., Sanofi S.A., Johnson & Johnson, Baxter International, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.
Scope of the Study
Market Segments Covered in the Report:
By End User
By Disease Type
- Active Multiple Myeloma
- Smoldering Multiple Myeloma
By Drug Type
- Protease Inhibitors
- Monoclonal Antibody
- Chemotherapy
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Bristol Myers Squibb Company
- Amgen, Inc.
- AbbVie, Inc.
- Sanofi S.A.
- Johnson & Johnson
- Baxter International, Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Multiple Myeloma Market, by End User
1.4.2 LAMEA Multiple Myeloma Market, by Disease Type
1.4.3 LAMEA Multiple Myeloma Market, by Drug Type
1.4.4 LAMEA Multiple Myeloma Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Trials and Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. LAMEA Multiple Myeloma Market by End User
4.1 LAMEA Hospitals Market by Country
4.2 LAMEA Clinics Market by Country
4.3 LAMEA Others Market by Country
Chapter 5. LAMEA Multiple Myeloma Market by Disease Type
5.1 LAMEA Active Multiple Myeloma Market by Country
5.2 LAMEA Smoldering Multiple Myeloma Market by Country
Chapter 6. LAMEA Multiple Myeloma Market by Drug Type
6.1 LAMEA Protease Inhibitors Market by Country
6.2 LAMEA Monoclonal Antibody Market by Country
6.3 LAMEA Chemotherapy Market by Country
6.4 LAMEA Others Market by Country
Chapter 7. LAMEA Multiple Myeloma Market by Country
7.1 Brazil Multiple Myeloma Market
7.1.1 Brazil Multiple Myeloma Market by End User
7.1.2 Brazil Multiple Myeloma Market by Disease Type
7.1.3 Brazil Multiple Myeloma Market by Drug Type
7.2 Argentina Multiple Myeloma Market
7.2.1 Argentina Multiple Myeloma Market by End User
7.2.2 Argentina Multiple Myeloma Market by Disease Type
7.2.3 Argentina Multiple Myeloma Market by Drug Type
7.3 UAE Multiple Myeloma Market
7.3.1 UAE Multiple Myeloma Market by End User
7.3.2 UAE Multiple Myeloma Market by Disease Type
7.3.3 UAE Multiple Myeloma Market by Drug Type
7.4 Saudi Arabia Multiple Myeloma Market
7.4.1 Saudi Arabia Multiple Myeloma Market by End User
7.4.2 Saudi Arabia Multiple Myeloma Market by Disease Type
7.4.3 Saudi Arabia Multiple Myeloma Market by Drug Type
7.5 South Africa Multiple Myeloma Market
7.5.1 South Africa Multiple Myeloma Market by End User
7.5.2 South Africa Multiple Myeloma Market by Disease Type
7.5.3 South Africa Multiple Myeloma Market by Drug Type
7.6 Nigeria Multiple Myeloma Market
7.6.1 Nigeria Multiple Myeloma Market by End User
7.6.2 Nigeria Multiple Myeloma Market by Disease Type
7.6.3 Nigeria Multiple Myeloma Market by Drug Type
7.7 Rest of LAMEA Multiple Myeloma Market
7.7.1 Rest of LAMEA Multiple Myeloma Market by End User
7.7.2 Rest of LAMEA Multiple Myeloma Market by Disease Type
7.7.3 Rest of LAMEA Multiple Myeloma Market by Drug Type
Chapter 8. Company Profiles
8.1 Johnson & Johnson
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental &Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Trials and Approvals:
8.1.5.2 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 Novartis AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Product Launches and Product Expansions:
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Trials and Approvals:
8.4 Amgen, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.4.5.2 Acquisition and Mergers:
8.5 AbbVie, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Baxter International, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.7 Teva Pharmaceutical Industries Ltd.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Product Launches and Product Expansions:
8.8 Pfizer, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional & Segmental Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.9 Bristol Myers Squibb Company
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Trials and Approvals:
8.9.5.2 Acquisition and Mergers:
8.10. Takeda Pharmaceutical Company Limited
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
TABLE 1 LAMEA Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Multiple Myeloma Market
TABLE 4 Product Launches And Product Expansions– Multiple Myeloma Market
TABLE 5 Acquisition and Mergers– Multiple Myeloma Market
TABLE 6 Trials and approvals – Multiple Myeloma Market
TABLE 7 LAMEA Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 8 LAMEA Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 9 LAMEA Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 10 LAMEA Hospitals Market by Country, 2023 - 2029, USD Million
TABLE 11 LAMEA Clinics Market by Country, 2019 - 2022, USD Million
TABLE 12 LAMEA Clinics Market by Country, 2023 - 2029, USD Million
TABLE 13 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 14 LAMEA Others Market by Country, 2023 - 2029, USD Million
TABLE 15 LAMEA Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 16 LAMEA Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 17 LAMEA Active Multiple Myeloma Market by Country, 2019 - 2022, USD Million
TABLE 18 LAMEA Active Multiple Myeloma Market by Country, 2023 - 2029, USD Million
TABLE 19 LAMEA Smoldering Multiple Myeloma Market by Country, 2019 - 2022, USD Million
TABLE 20 LAMEA Smoldering Multiple Myeloma Market by Country, 2023 - 2029, USD Million
TABLE 21 LAMEA Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 22 LAMEA Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 23 LAMEA Protease Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 24 LAMEA Protease Inhibitors Market by Country, 2023 - 2029, USD Million
TABLE 25 LAMEA Monoclonal Antibody Market by Country, 2019 - 2022, USD Million
TABLE 26 LAMEA Monoclonal Antibody Market by Country, 2023 - 2029, USD Million
TABLE 27 LAMEA Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 28 LAMEA Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 29 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 30 LAMEA Others Market by Country, 2023 - 2029, USD Million
TABLE 31 LAMEA Multiple Myeloma Market by Country, 2019 - 2022, USD Million
TABLE 32 LAMEA Multiple Myeloma Market by Country, 2023 - 2029, USD Million
TABLE 33 Brazil Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 34 Brazil Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 35 Brazil Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 36 Brazil Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 37 Brazil Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 38 Brazil Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 39 Brazil Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 40 Brazil Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 41 Argentina Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 42 Argentina Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 43 Argentina Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 44 Argentina Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 45 Argentina Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 46 Argentina Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 47 Argentina Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 48 Argentina Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 49 UAE Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 50 UAE Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 51 UAE Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 52 UAE Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 53 UAE Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 54 UAE Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 55 UAE Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 56 UAE Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 57 Saudi Arabia Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 58 Saudi Arabia Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 59 Saudi Arabia Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 60 Saudi Arabia Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 61 Saudi Arabia Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 62 Saudi Arabia Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 63 Saudi Arabia Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 64 Saudi Arabia Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 65 South Africa Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 66 South Africa Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 67 South Africa Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 68 South Africa Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 69 South Africa Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 70 South Africa Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 71 South Africa Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 72 South Africa Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 73 Nigeria Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 74 Nigeria Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 75 Nigeria Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 76 Nigeria Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 77 Nigeria Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 78 Nigeria Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 79 Nigeria Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 80 Nigeria Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 81 Rest of LAMEA Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 82 Rest of LAMEA Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 83 Rest of LAMEA Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 84 Rest of LAMEA Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 85 Rest of LAMEA Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 86 Rest of LAMEA Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 87 Rest of LAMEA Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 88 Rest of LAMEA Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 89 Key information –Johnson & Johnson
TABLE 90 Key Information – Novartis AG
TABLE 91 Key Information – Sanofi S.A.
TABLE 92 Key Information – Amgen, Inc.
TABLE 93 Key information – AbbVie, Inc.
TABLE 94 Key Information – Baxter International, Inc.
TABLE 95 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 96 Key Information – Pfizer, Inc.
TABLE 97 Key Information – Bristol Myers Squibb Company
TABLE 98 Key Information – Takeda Pharmaceutical Company Limited
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 SWOT analysis: Johnson & Johnson
FIG 5 Recent strategies and developments: Novartis AG
FIG 6 Recent strategies and developments: Sanofi S.A.